Shree Ganesh Biotech (India) Ltd

Shree Ganesh Biotech (India) Ltd has submitted its Annual Report for the financial year 2025-26, along with the Notice of its 16th Annual General Meeting (AGM). The AGM is scheduled to be held on Monday, September 28, 2026, at the company's registered office in Kolkata. Key agenda items include the adoption of audited financial statements for FY26 and the re-appointment of a director retiring by rotation. The report also details the company's corporate information, board of directors, key managerial personnel, board committees, statutory auditors, bankers, and contact information.

Shree Ganesh Biotech (India) Ltd has announced its 16th Annual General Meeting (AGM) to be held on September 28, 2026, at its registered office in Kolkata. The meeting will focus on adopting the audited financial statements for the fiscal year ended March 31, 2026, and the reports of the Board of Directors and Independent Auditors. Additionally, the AGM will address the re-appointment of Mr. Aman Patel as a Director, who retires by rotation. The notice also details procedures for proxy appointments, electronic voting, and the closure of the Register of Members and Share Transfer Register from September 21 to September 28, 2026.

Shree Ganesh Biotech (India) Ltd has announced an update to its corporate information, specifically regarding its official website. The company has launched a new website, which is now live at www.shreeganeshbiotech.bar. Shareholders and the public are requested to update their records to reflect this change and remove any old website details. This announcement is for informational purposes to ensure accurate contact and online presence information.

Shree Ganesh Biotech (India) Ltd has informed the stock exchanges that as of June 30, 2026, there are no remaining unutilized funds from any past public issue, rights issue, preferential issue, or qualified institutional placement (QIP). This disclosure is made pursuant to SEBI regulations regarding the utilization of proceeds from such fundraising activities. Consequently, no further information or annexure is required to be provided.

Shree Ganesh Biotech (India) Ltd announced that its Board of Directors, in a meeting held on August 4, 2026, considered and approved the un-audited standalone financial results for the quarter ended June 30, 2026. The financial results were reviewed by the Audit Committee and have undergone a limited review by the statutory auditors. The company operates in a single segment.

Shree Ganesh Biotech (India) Ltd announced that its Board of Directors, in a meeting held on August 4, 2026, approved the un-audited financial results for the quarter ended June 30, 2026. The company operates in a single segment. The financial results were reviewed by the Audit Committee and have undergone a limited review by the statutory auditors. Previous periods' figures have been re-grouped or re-arranged as necessary. Provisions for taxation will be made at year-end.

Shree Ganesh Biotech (India) Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026. The date for the board meeting to approve these results will be communicated separately.

Shree Ganesh Biotech (India) Ltd's audited financial results for the year ended March 31, 2026, show a total income of ₹644.27 lakhs and total expenses of ₹592.86 lakhs. The company reported a net profit after tax of ₹37.76 lakhs. Gross revenue from the sale of products was ₹497.05 lakhs. The Board meeting, which commenced and concluded on May 14, 2026, approved these results with an unmodified audit opinion.

Shree Ganesh Biotech (India) Ltd. has declared that as of March 31, 2026, and the present date, the company has no unutilized funds remaining from the proceeds of any public issue, rights issue, preferential issue, or qualified institutional placement (QIP) undertaken at any time in the past. Consequently, the company will not be providing information as per Annexure-A, as required by SEBI regulations and circulars.

Shree Ganesh Biotech (India) Ltd's board approved the audited financial results for the year ended March 31, 2026. Gross revenue from the sale of products stood at ₹497.05 lakhs for FY26, compared to ₹2,295.76 lakhs in the previous year. The company reported a net profit after tax of ₹37.76 lakhs for the year ended March 31, 2026.